The burden and outcome of nasopharyngeal carcinoma in Sweden
Introduction: The purpose of this study is to present the nationwide disease burden and survival of nasopharyngeal carcinoma (NPC) in Sweden. The subcohort from the Stockholm-Gotland region was included to investigate the prevalence of Epstein-Barr virus (EBV) in NPC and to describe pattern of relap...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Medical Journals Sweden
2025-07-01
|
| Series: | Acta Oncologica |
| Subjects: | |
| Online Access: | https://medicaljournalssweden.se/actaoncologica/article/view/43700 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850099104026198016 |
|---|---|
| author | Evelina Gille Anders Näsman Madeleine Helmersson Elin Marsk Antti Mäkitie Lalle Hammarstedt-Nordenvall |
| author_facet | Evelina Gille Anders Näsman Madeleine Helmersson Elin Marsk Antti Mäkitie Lalle Hammarstedt-Nordenvall |
| author_sort | Evelina Gille |
| collection | DOAJ |
| description | Introduction: The purpose of this study is to present the nationwide disease burden and survival of nasopharyngeal carcinoma (NPC) in Sweden. The subcohort from the Stockholm-Gotland region was included to investigate the prevalence of Epstein-Barr virus (EBV) in NPC and to describe pattern of relapse.
Methods: This population-based nationwide study included patients diagnosed with NPC in Sweden during 2008–2021. The series was retrieved from the Swedish Head and Neck Cancer Register. Age at diagnosis, sex, tumor histopathology, stage, treatment intent, treatment, radiation dose, follow-up time, time to relapse, and site of relapse were recorded. The Stockholm-Gotland region series was used to obtain an updated histopathological analysis including EBV status and to analyze site of relapse.
Results: The nationwide study cohort comprised 399 patients, 33% were female. Mean age at diagnosis did not differ between the sexes: 56.3 years for females, 57.5 years for males. Seventy-one percent presented with Stage III or IV. The 5-year overall survival (OS) was 73.2%. In the regional cohort, 73.9% were EBV positive. In the competing risk analysis, the cumulative incidence of distant metastatic relapse was higher than that of local and/or regional relapse at 5 years (18.7% vs. 12.4%). However, the confidence intervals were wide, and the difference should be interpreted with caution.
Interpretation: The survival outcome in our study seems comparable to previous studies in nonendemic countries. There was a high percentage of EBV-positive tumors compared with the previous studies in nonendemic countries.
|
| format | Article |
| id | doaj-art-10837eec084c484f8f4ae2ec4140b3dd |
| institution | DOAJ |
| issn | 1651-226X |
| language | English |
| publishDate | 2025-07-01 |
| publisher | Medical Journals Sweden |
| record_format | Article |
| series | Acta Oncologica |
| spelling | doaj-art-10837eec084c484f8f4ae2ec4140b3dd2025-08-20T02:40:33ZengMedical Journals SwedenActa Oncologica1651-226X2025-07-016410.2340/1651-226X.2025.43700The burden and outcome of nasopharyngeal carcinoma in SwedenEvelina Gille0https://orcid.org/0009-0005-4268-1929Anders Näsman1Madeleine Helmersson2Elin Marsk3Antti Mäkitie4Lalle Hammarstedt-Nordenvall5Division of Ear, Nose and Throat Diseases, Department of Clinical Sciences, Intervention and Technology, Karolinska Institute and Karolinska Hospital, Stockholm, SwedenDepartment of Oncology-Pathology, Karolinska Institute, Bioclinicum, Karolinska University Hospital, Stockholm, Sweden; Department of Clinical Pathology, Karolinska University Hospital, Stockholm, SwedenRegional Cancer Center West, Western Sweden Health Care Region, Gothenburg, SwedenDivision of Ear, Nose and Throat Diseases, Department of Clinical Sciences, Intervention and Technology, Karolinska Institute and Karolinska Hospital, Stockholm, SwedenDivision of Ear, Nose and Throat Diseases, Department of Clinical Sciences, Intervention and Technology, Karolinska Institute and Karolinska Hospital, Stockholm, Sweden; Department of Otorhinolaryngology – Head and Neck Surgery, University of Helsinki and Helsinki University Hospital, Helsinki, Finland; Research Program in Systems Oncology, Faculty of Medicine, University of Helsinki, Helsinki, Finland Division of Ear, Nose and Throat Diseases, Department of Clinical Sciences, Intervention and Technology, Karolinska Institute and Karolinska Hospital, Stockholm, SwedenIntroduction: The purpose of this study is to present the nationwide disease burden and survival of nasopharyngeal carcinoma (NPC) in Sweden. The subcohort from the Stockholm-Gotland region was included to investigate the prevalence of Epstein-Barr virus (EBV) in NPC and to describe pattern of relapse. Methods: This population-based nationwide study included patients diagnosed with NPC in Sweden during 2008–2021. The series was retrieved from the Swedish Head and Neck Cancer Register. Age at diagnosis, sex, tumor histopathology, stage, treatment intent, treatment, radiation dose, follow-up time, time to relapse, and site of relapse were recorded. The Stockholm-Gotland region series was used to obtain an updated histopathological analysis including EBV status and to analyze site of relapse. Results: The nationwide study cohort comprised 399 patients, 33% were female. Mean age at diagnosis did not differ between the sexes: 56.3 years for females, 57.5 years for males. Seventy-one percent presented with Stage III or IV. The 5-year overall survival (OS) was 73.2%. In the regional cohort, 73.9% were EBV positive. In the competing risk analysis, the cumulative incidence of distant metastatic relapse was higher than that of local and/or regional relapse at 5 years (18.7% vs. 12.4%). However, the confidence intervals were wide, and the difference should be interpreted with caution. Interpretation: The survival outcome in our study seems comparable to previous studies in nonendemic countries. There was a high percentage of EBV-positive tumors compared with the previous studies in nonendemic countries. https://medicaljournalssweden.se/actaoncologica/article/view/43700Nasopharyngeal carcinomaEpstein-Barr VirusSwedish Head and Neck Cancer Register |
| spellingShingle | Evelina Gille Anders Näsman Madeleine Helmersson Elin Marsk Antti Mäkitie Lalle Hammarstedt-Nordenvall The burden and outcome of nasopharyngeal carcinoma in Sweden Acta Oncologica Nasopharyngeal carcinoma Epstein-Barr Virus Swedish Head and Neck Cancer Register |
| title | The burden and outcome of nasopharyngeal carcinoma in Sweden |
| title_full | The burden and outcome of nasopharyngeal carcinoma in Sweden |
| title_fullStr | The burden and outcome of nasopharyngeal carcinoma in Sweden |
| title_full_unstemmed | The burden and outcome of nasopharyngeal carcinoma in Sweden |
| title_short | The burden and outcome of nasopharyngeal carcinoma in Sweden |
| title_sort | burden and outcome of nasopharyngeal carcinoma in sweden |
| topic | Nasopharyngeal carcinoma Epstein-Barr Virus Swedish Head and Neck Cancer Register |
| url | https://medicaljournalssweden.se/actaoncologica/article/view/43700 |
| work_keys_str_mv | AT evelinagille theburdenandoutcomeofnasopharyngealcarcinomainsweden AT andersnasman theburdenandoutcomeofnasopharyngealcarcinomainsweden AT madeleinehelmersson theburdenandoutcomeofnasopharyngealcarcinomainsweden AT elinmarsk theburdenandoutcomeofnasopharyngealcarcinomainsweden AT anttimakitie theburdenandoutcomeofnasopharyngealcarcinomainsweden AT lallehammarstedtnordenvall theburdenandoutcomeofnasopharyngealcarcinomainsweden AT evelinagille burdenandoutcomeofnasopharyngealcarcinomainsweden AT andersnasman burdenandoutcomeofnasopharyngealcarcinomainsweden AT madeleinehelmersson burdenandoutcomeofnasopharyngealcarcinomainsweden AT elinmarsk burdenandoutcomeofnasopharyngealcarcinomainsweden AT anttimakitie burdenandoutcomeofnasopharyngealcarcinomainsweden AT lallehammarstedtnordenvall burdenandoutcomeofnasopharyngealcarcinomainsweden |